Consun Pharmaceutical Group Limited (HKG: 1681)

Market Cap	6.99B
Revenue (ttm)	2.94B
Net Income (ttm)	898.71M
Shares Out	826.88M
EPS (ttm)	1.11
PE Ratio	7.59
Forward PE	7.09
Dividend	0.60 (7.08%)
Ex-Dividend Date	Sep 5, 2024

Volume	49,000
Open	8.50
Previous Close	8.50
Day's Range	8.49 - 8.59
52-Week Range	4.38 - 8.88
Beta	0.62
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 21, 2024

About Consun Pharmaceutical Group

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function ass...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 3,127
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1681

Financial Performance

In 2023, Consun Pharmaceutical Group's revenue was 2.59 billion, an increase of 10.71% compared to the previous year's 2.34 billion. Earnings were 784.53 million, an increase of 14.88%.

Financial numbers in CNY